Don't mistake Stryker's latest $500 million deal in the spine market as a simple tuck-in acquisition, says one analyst while another says it could help Stryker give Medtronic a run for its money.
Analysts say that Stryker's purchase of a small but fast-growing public company in the complex spine market should help its own struggling spine business.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Stryker is shelling out top dollar to buy Novadaq, a maker of fluorescence imaging technologies that allows surgeons to see blood flow in vessels during surgery in real time.
The shift from volume to value is no where more apparent than in the orthopedics specialty where vendors that once obsessed over titanium and steel are now focusing on services to manage the bundled payment era.
Stryker is launching its Triathlon total knee on its Mako robotic system, reportedly priced at $1 million, at a time of bundled payments and cost consciousness in joint replacement procedures.
Smart medtech companies are realizing that they have to be partners to hospitals and not simply vendors selling widgets.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.